TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00970762
Drug: Rocuronium 0.15 mg/kg maintenance dose
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rocuronium 0.15 mg/kg maintenance dose following the intubating dose
Study: NCT00970762
Drug: Rocuronium 0.2 mg/kg maintenance
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rocuronium 0.2 mg/kg maintenance dose following the intubating dose
Study: NCT00970762
Drug: Vecuronium 0.1 mg/kg intubating dose
DrugBank: Vecuronium (DB01339)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vecuronium 0.1 mg/kg intubating dose
Study: NCT00970762
Drug: Vecuronium 0.025 mg/kg maintenance dose
DrugBank: Vecuronium (DB01339)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vecuronium 0.025 mg/kg maintenance dose following the intubating dose
Study: NCT01159639
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: patients with inappropriate response to aspirin 300 mg after CABG, assessed by multiple electrode aggregometry are randomized to receive clopidogrel 75 mg daily dose
Study: NCT03958630
Drug: 11C-ER176
Normalized name: 11C-choline
DrugBank: Choline C 11 (DB09277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET biomarker for inflammation
Study: NCT03958630
Drug: 11C-PIB
Normalized name: 11C-choline
DrugBank: Choline C 11 (DB09277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET biomarker for amyloid
Study: NCT00222872
Drug: Parathyroid Hormone-related Protein
Normalized name: Parathyroid Hormone-Related Protein 1-36
DrugBank: Parathyroid Hormone-Related Protein 1-36 (DB16278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTHrP(1-36) starting at 500 micrograms, then increasing by 125 micrograms up to a maximum of 1,500 micrograms.
Study: NCT00330148
Drug: melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d
DrugBank: Nifurtimox (DB11820)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03170817
Drug: N-13 ammonia
DrugBank: Ammonia (DB11118)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-10 mCi intravenous injection of N-13 ammonia radiopharmaceutical at rest and at stress
Study: NCT03170817
Drug: Regadenoson
Normalized name: Regadenoson
DrugBank: Regadenoson (DB06213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.4 mg/5mL intravenous injection to induce pharmacologic stress (Astellas Pharma US, Inc.)
Study: NCT00242411
Drug: Budesonide/Formoterol Turbuhaler
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00045773
Drug: Sertraline
Normalized name: Sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 - 200mg, once per day for 12 weeks.
Study: NCT02729064
Drug: Humulin R
Normalized name: HumuLIN R
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study subjects will receive intranasal insulin (Humulin R) via a metered nasal dispenser.
Study: NCT01815736
Drug: ATV
Normalized name: PrenatVite Tablet
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg capsule administered orally once daily
Study: NCT01815736
Drug: COBI
Normalized name: Ricobid H
DrugBank: Cobimetinib (DB05239)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 150 mg tablet administered orally once daily
Study: NCT03656393
Drug: Gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gefitinib (250 mg, orally, every day) for 56 days
Study: NCT03656393
Drug: Vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinorelbine (60 mg/m2, orally, Once every three weeks) for 6 weeks
Study: NCT01905150
Drug: G-FLIP-DM
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: G-FLIP-DM is low doses of Gemcitabine, Fluorouracil \[5FU\], Leucovorin, Irinotecan, Oxaliplatin, Docetaxel and Mitomycin C
Study: NCT03656393
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin (AUC5, intravenously drip, once a week) for 6 weeks
Study: NCT01363570
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intra-vitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2. For those requiring additional injections, patients will receive monthly treatment up to a maximum of 6 months total.
Study: NCT02114619
Drug: Low dose of I-131
Normalized name: iobenguane I-131
DrugBank: Iobenguane (DB06704)
Approvals — FDA: no, EMA: no, PMDA: no
Description: We wil administer 100 micro currie of iodine per thyroid gram
Study: NCT01602029
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ondansetron added to TAU Ondansetron will be administered in 8mg once daily dose
Study: NCT00728910
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg QD for 4 weeks
Study: NCT00728910
Drug: ER Niacin
Normalized name: Leader Niacin 500mg Tablet
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 mg QD added to atorvastatin and ABT335 for 10 weeks
Study: NCT00189176
Drug: Tetrathiomolybdate
Normalized name: Tetrathiomolybdate
DrugBank: Tetrathiomolybdate (DB05088)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00518895
Drug: dacarbazine plus Genasense
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Protocol therapy will be administered in 21-day cycles for up to 8 cycles. Subjects in the dacarbazine plus Genasense group will receive Genasense 7 mg/kg/day by continuous intravenous infusion beginning on Day 1 and continuing for 5 days (120 hours) plus dacarbazine 1000 mg/m2 as a 60-minute intravenous infusion immediately following the conclusion of the Genasense infusion. Subjects who are responding or have stable disease after 8 cycles of therapy may, at the Investigator's discretion, continue that same therapy for up to 8 additional cycles.
Study: NCT00518895
Drug: dacarbazine plus placebo
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Protocol therapy will be administered in 21-day cycles for up to 8 cycles. Subjects in the dacarbazine plus placebo group will receive placebo (that is, locally available commercial 0.9% Sodium Chloride Injection) by continuous intravenous infusion beginning on Day 1 and continuing for 5 days (120 hours) plus dacarbazine 1000 mg/m2 as a 60-minute intravenous infusion immediately following the conclusion of the placebo infusion. Subjects who are responding or have stable disease after 8 cycles of therapy may, at the Investigator's discretion, continue that same therapy for up to 8 additional cycles.
Study: NCT03410004
Drug: Chidamide
Normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Chidamide 30mg orally BIW. Treatment cycles are repeated every 4 weeks.
Study: NCT03880136
Drug: CTP-543
Normalized name: CTP-SOMATROPIN FUSION PROTEIN
DrugBank: Somatrogon (DB14960)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Once daily dosing
Study: NCT01737307
Drug: Fluoride varnish
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride Varnish (NaF 5%)
Study: NCT00230334
Drug: Gleevec
Normalized name: Gleevec
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04413344
Drug: Bromocriptine
Normalized name: Bromocriptine
DrugBank: Bromocriptine (DB01200)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TW-012R: Each tablet contains 2.87 mg of bromocriptine mesilate (JP) (2.5 mg of bromocriptine)
Study: NCT00019461
Drug: carboxyamidotriazole
Normalized name: Carboxyamidotriazole
DrugBank: Carboxyamidotriazole (DB11960)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02076386
Drug: Dolutegravir
Normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prospective, non-interventional study of the use of doluetegravir as part of an antiretroviral combination therapy in routine daily practice in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.
Study: NCT02651870
Drug: Candesartan 16mg
Normalized name: CANDESARTAN 16MG/HCTZ 12.5MG TAB
DrugBank: Candesartan (DB13919)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02651870
Drug: Amlodipine 5mg
Normalized name: LEVAMLODIPINE 5MG TAB
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02651870
Drug: Amlodipine 10mg
Normalized name: AMLODIPINE 10MG/VALSARTAN 160MG TAB
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00646399
Drug: Pagibaximab 50 mg/mL
DrugBank: Pagibaximab (DB17786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pagibaximab 100 mg/kg dosed on Days 0, 1, 2, 9, 16 and 23
Study: NCT01149720
Drug: Tivantinib (ARQ 197) Capsule
Normalized name: Tivantinib
DrugBank: Tivantinib (DB12200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral BID 360 mg dose (Capsule C: 6 X 60 mg) of ARQ 197 at least 1 hour before or 2 hours after a meal for 7 days
Study: NCT02314481
Drug: Vemurafenib
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Film coated tablet
Study: NCT02314481
Drug: Alectinib
Normalized name: Alectinib
DrugBank: Alectinib (DB11363)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: capsule
Study: NCT02314481
Drug: Trastuzumab emtansine
Normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Powder for concentrate for solution for infusion
Study: NCT01051557
Drug: Perifosine
Normalized name: Perifosine
DrugBank: Perifosine (DB06641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01051557
Drug: Temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT02392026
Drug: Metronidazole Gel
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole Vaginal Gel 1.3% administered via applicator
Study: NCT00613821
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 milliliter intrauterine infusion of 4% lidocaine, infusion will be placed slowly over 3 minutes.
Study: NCT00613821
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard paracervical block (8 milliliter 1% lidocaine at 4 and 8 o'clock at the cervical-vaginal reflection) will be placed.
Study: NCT00137345
Drug: sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00166868
Drug: Lactobacillus casei rhamnosus (Lcr35)
Normalized name: Lactobacillus casei rhamnosus
DrugBank: Lactobacillus casei (DB16541)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00166868
Drug: Neomycin
Normalized name: Neomycin
DrugBank: Neomycin (DB00994)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02553642
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Monotherapy Treatment - Nivolumab 240 mg flat dose Dosed q 2 weeks~OR~- Nivolumab 480 mg flat dose Dosed q 4 weeks~for up to 2 years from 1st dose of nivolumab or until loss of clinical benefit
Study: NCT02553642
Drug: Nivolumab plus Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Combination Treatment~* Ipilimumab 3 mg/kg~* Nivolumab 1 mg/kg Dosed q 3 weeks x 4 doses
Study: NCT04069221
Drug: Single oral dose of 400 mg OZ439
Normalized name: magnesium hydroxide
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single oral dose of 400 mg OZ439
Study: NCT04069221
Drug: Single oral dose of cobicistat
Normalized name: Cobicistat
DrugBank: Cobicistat (DB09065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single oral dose of 150 mg cobicistat
Study: NCT04005729
Drug: Cangrelor 50 MG
Normalized name: cangrelor 50 MG
DrugBank: Cangrelor (DB06441)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 30 mcg/kg bolus, then 4h infusion 4 mcg/kg/min
Study: NCT01736943
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib will be given twice a week subcutaneously (under the skin) for two weeks in every 3 week cycle.
Study: NCT01736943
Drug: Doxil
Normalized name: Doxil
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxil or LipoDox will also be given through a venous catheter (inside your vein). Doxil or LipoDox will be given over 60 to 90 minutes on Day 4 of every 21-day cycle.
Study: NCT01431495
Drug: Pidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pidogrel(R)75 mg/day for period ranging from 1 to 6 months.
Study: NCT01018758
Drug: Palonosetron
Normalized name: Palonosetron
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palonosetron will be given as an intravenous bolus at the dose of 250 micrograms over 30 seconds beginning 30 minutes before chemotherapy.
Study: NCT01589367
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin HCl 500mg(morning/evening) PO daily x 1week Metformin HCl 1000mg(morning)and 500mg(evening)PO daily x 1week Metformin HCl 1000mg(morning/evening) PO daily x 22weeks
Study: NCT01149720
Drug: Tivantinib (ARQ 197) Tablet
Normalized name: Tivantinib
DrugBank: Tivantinib (DB12200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral BID 360 mg dose (Tablet: 3 x 120 mg) of ARQ 197 under fed conditions for 7 days
Study: NCT01431495
Drug: Plavix
Normalized name: Plavix
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Plavix(R) 75 mg/day for period ranging from 1 to 6 months.
Study: NCT01932697
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00084344
Drug: 4-hydroxytamoxifen
Normalized name: 4-hydroxytamoxifen
DrugBank: Afimoxifene (DB04468)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01852318
Drug: pregabalin 75mg daily for 12 weeks
Normalized name: pregabalin 75 MG
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: oral pregabalin 75mg daily for 12 weeks
Study: NCT01852318
Drug: fexofenadine 60 mg daily for 12 weeks
Normalized name: fexofenadine hydrochloride 60 MG
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: fexofenadine 60 mg daily for 12 weeks
Study: NCT01882543
Drug: AQX-1125
Normalized name: AQX-1125
DrugBank: AQX-1125 (DB13012)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic SHIP1 activator
Study: NCT03788603
Drug: Rogaratinib (BAY1163877)
Normalized name: Rogaratinib
DrugBank: Rogaratinib (DB15078)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rogaratinib will be administered on 20 days in Cycle 1 (single dosing on Day 1 and twice daily dosing on Days 3-21). In Cycles ≥2, rogaratinib will be administered twice daily for 21 days, with cycles repeated every 21 days. Treatment will be continued until death, tumor progression, unacceptable toxicity, consent withdrawal, or until another criterion is met for withdrawal from the study at the discretion of the investigator.
Study: NCT01149720
Drug: Tivantinib (ARQ 197) Capsule D, oral
DrugBank: Tivantinib (DB12200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral BID 360 mg dose (Capsule D: 3 x 120 mg) of ARQ 197 under fed conditions in the extension phase
Study: NCT01398501
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral, 200 to 400 mg QD or BID
Study: NCT02227277
Drug: Peg-IFN-α2b
Normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arm 1: At week 4 of the treatment, ART will be interrupted. Viral load will be monitored every 2 weeks. ART will be resumed at the earlier of a) a single measurement of VL \> 50 c/ml or b) 16 weeks of treatment, and subjects will be observed for the remaining 4 weeks (total of 20 weeks on treatment).~Arm 2: In week 4, participants in arm 2 will add peg-IFN-α-2b to their ART regimen for a period of 20 weeks.
Study: NCT03943498
Drug: Fingolimod
Normalized name: Fingolimod
DrugBank: Fingolimod (DB08868)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO daily for 4 weeks
Study: NCT03943498
Drug: Fingolimod Hydrochloride
Normalized name: Fingolimod Hydrochloride
DrugBank: Fingolimod (DB08868)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT03050437
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cisplatin is added to Pem/cis arm
Study: NCT03050437
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pem is applied to both arms
Study: NCT04701593
Drug: Triamcinolone Acetonide 40mg/mL
Normalized name: TRIAMCINOLONE ACETONIDE 40MG/ML INJ,SUSP
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sub-tenon irrigation 1cc
Study: NCT00245011
Drug: ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ifosfamide administered IV.
Study: NCT01793038
Drug: clomiphene citrate-uFSH arm
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: clomiphene citrate 50 mg tablets twice /day for 5 days plus 37.5 IU uFSH IM injections daily for 10 days
Study: NCT02667925
Drug: Intraperitoneal cisplatin with nanocis
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive an intraperitoneal chemotherapy combined to a radiotracer in order to assess the intraperitoneal distribution of the chemotherapy
Study: NCT02849743
Drug: Syntocinon
Normalized name: Syntocinon
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The active substance of Syntocinon is a synthetic nonapeptide identical to the posterior pituitary hormone oxytocin.
Study: NCT01759706
Drug: PONV prophylaxis with Ondansetron + Dexamethasone
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative nausea and vomiting prophylaxis with Ondansetron + Dexamethasone.
Study: NCT01759706
Drug: Pre-anesthetic medication with diazepam
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Premedication before general anesthesia
Study: NCT01759706
Drug: Preoperative bowel preparation with sodium phosphate
Normalized name: cranberry preparation
DrugBank: Cranberry (DB10631)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative bowel preparation with oral assumption of sodium phosphate
Study: NCT01558219
Drug: cabacitaxel
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Jevtana® (cabazitaxel) 16 mg/m2 IV in 1 hour on day 1 given every second week
Study: NCT01200706
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amoxicillin 50mg/kg/day given in two different administration schemes
Study: NCT02168491
Drug: Lixisenatide
Normalized name: Lixisenatide
DrugBank: Lixisenatide (DB09265)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be switched to basal insulin glargine (Lantus, once daily in the morning) and GLP-1 receptor agonist Lixisenatide (Lyxumia, once daily in the morning before breakfast; days 1-14 10 µg thereafter 20 µg). The (mean) daily dose of premixed insulin will be calculated based on the records of the run in period. The initial dose of insulin glargine will be adjusted at about 60% of the daily insulin dose of premixed insulin. This is based on the observed reduction of required insulin dose described in recent literature upon initiation with a GLP-1 agonist.
Study: NCT02168491
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will be switched to basal insulin glargine (Lantus, once daily in the morning) and GLP-1 receptor agonist Lixisenatide (Lyxumia, once daily in the morning before breakfast; days 1-14 10 µg thereafter 20 µg). The (mean) daily dose of premixed insulin will be calculated based on the records of the run in period. The initial dose of insulin glargine will be adjusted at about 60% of the daily insulin dose of premixed insulin. This is based on the observed reduction of required insulin dose described in recent literature upon initiation with a GLP-1 agonist.
Study: NCT03175081
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient undergo elective laparoscopic sleeve gastrectomy will receive 20mL of 150mg ropivacaine (0.75%) diluted in 180mL normal saline to be injected through a catheter along the greater curvature and left subdiaphragmatic region of the stomach at the end of the surgical procedure. After the surgery, the medical doctors or nurses in the ward that is not otherwise involved in this research will assess and record the pain score using visual analog scale (VAS) (0-10). The abdomen and shoulder tip pain intensity will be rated at two, four, six, eight, 24 and 48 hours postoperatively.
Study: NCT04164121
Drug: Phenlarmide Tablets
Normalized name: Octanedioic acid hydroxyamide phenylamide
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration was conducted on an empty stomach, and the drug was administered once a day on day 1 and once a day from day 8 to day 17.
Study: NCT01325311
Drug: Cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01325311
Drug: Genistein
Normalized name: Genistein
DrugBank: Genistein (DB01645)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT00650494
Drug: Valacyclovir Hydrochloride Tablets 1000mg
Normalized name: Valacyclovir Hydrochloride
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1000mg, single dose fed
Study: NCT01980680
Drug: hCG
Normalized name: HCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04518618
Drug: Naloxone
Normalized name: Naloxone
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spinal anesthesia will be performed with injection of 2.5 ml which will be composed of 10 mg hyperbaric bupivacaine (2 ml) and fentanyl 25 ug combined with 20 ugs naloxone in 0.5 ml
Study: NCT01732822
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 90 mg bd (and Clopidogrel placebo od) taken orally as tablets
Study: NCT01732822
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel 75 mg od (and Ticagrelor placebo bd) taken orally as tablets